Model-based cost-effectiveness analysis of oral antivirals against SARS-CoV-2 in Korea.

ABSTRACT:

Objectives

Many countries have authorized the emergency use of oral antiviral agents for patients with mild-to-moderate cases of coronavirus disease 2019 (COVID-19). We assessed the cost-effectiveness of these agents for reducing the number of severe COVID-19 cases and the burden on Korea's medical system.

Methods

Using an existing model, we estimated the number of people who would require hospital/intensive care unit (ICU) admission in Korea in 2022. The treatment scenarios included (1) all adult patients, (2) elderly patients only, and (3) adult patients with underlying diseases only, compared to standard care. Based on the current health system capacity, we calculated the incremental costs per severe case averted and hospital admission for each scenario.

Results

We

SUBMITTER: Jo Y 

PROVIDER: S-EPMC9350420 | biostudies-literature | 2022

REPOSITORIES: biostudies-literature